{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-329528","form_type":"8-K","ticker":"SPTX","cik":"0002042347","company_name":"Seaport Therapeutics, Inc.","filed_at":"2026-08-03T11:03:03+00:00","discovered_at":"2026-08-03T11:05:00.299865+00:00","generated_at":"2026-08-03T11:05:19.925041+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Seaport Therapeutics Q2 net loss $62.6M; cash $427.3M; GlyphAllo Phase 2b on track for 1H 2027","bullets":["Net loss of $62.6M for Q2 2026 vs $15.1M in Q2 2025; increase driven by one-time IPO-related stock-based compensation.","Cash, cash equivalents, and investments of $427.3M as of June 30, 2026, expected to fund operations into 2029.","Phase 2b BUOY-1 trial of GlyphAllo in MDD on track; topline data expected in 1H 2027.","Positive Phase 1 data for GlyphAgo: 6.8-fold bioavailability increase vs unmodified agomelatine; Phase 2a in GAD planned for 2H 2026.","Completed upsized IPO in May 2026 raising $260M gross proceeds; Sharon Mates appointed to board."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-329528","json":"https://secwatch.observer/filing/0001193125-26-329528.json","markdown":"https://secwatch.observer/filing/0001193125-26-329528.md","text":"https://secwatch.observer/filing/0001193125-26-329528.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526329528/0001193125-26-329528-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526329528/sptx-20260803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-03T11:05:19.925041+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}